ISCO.OB successfully manufactured its 1st scaled-up lots of stem cell-based skin creams, confirming that these unique products can be made in larger batch quantities and continues to meet Lifeline’s quality standards.
- This marks an important milestone in proving that 2 new technologies: the derivation of human parthenogenetic stem cells and the packaging and delivery of critical anti-aging ingredients, including those derived from stem cells can be scaled-up into a level of production suitable to meet commercial levels of demand;
- Lifeline Skin Care’s product development scientists have combined human parthenogenetic stem cell technology with the latest discoveries in skin rejuvenation to create its unique day and night skin care creams;
- ISCO’s scientists were the first to intentionally create human parthenogenetic stem cells from unfertilized human eggs, thus avoiding the ethical concerns of harming a viable human embryo.
ISCO’s therapeutic research team discovered that such cells had qualities that made them suitable for skin care products, thus leading to the formation of ISCO’s wholly-owned subsidiary, Lifeline Skin Care.